Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T14:15:55.120Z.
Consensus retrieved: 2026-10-06T09:26:53.443Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T14:15:55.120Z.
Quote observation: 2026-10-06T14:15:18.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: d0d16669f7a2c0e1646e6313a61118319ccaec2b3022f40527d46d929c834448
Forward PE Ratio (N/A) = Dated Quote Price ($6.24) / Consensus Forward EPS ($-2.43)
FORWARD PE RATIO
N/A
BioAge Labs Inc.
Market Cap
$234.82M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| BioAge Labs Inc. (BIOA) | $234.82M | N/A |
| Biodesix, Inc. (BDSX)vs › | $233.14M | N/A |
| Nautilus Biotechnolgy, Inc. (NAUT)vs › | $232.88M | N/A |
| Akebia Therapeutics, Inc. (AKBA)vs › | $235.26M | N/A |
| MacroGenics, Inc. (MGNX)vs › | $229.99M | N/A |
| Galectin Therapeutics Inc. (GALT)vs › | $237.74M | N/A |
| InflaRx N.V. (IFRX)vs › | $240.09M | N/A |
| High Tide Inc. (HITI)vs › | $240.32M | N/A |
| Keros Therapeutics, Inc. (KROS)vs › | $225.04M | N/A |
| Invivyd, Inc. (IVVD)vs › | $243.85M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $6.24, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-2.43 | $-2.89 – $-1.92 | 6 | n/m |
| 2027-12-31 | $-2.17 | $-2.64 – $-1.79 | 6 | n/m |
| 2028-12-31 | $-2.57 | $-3.31 – $-1.88 | 7 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
